Member Info for Rich62

Good news that Swedbank are buying, Rivaldo.

It would be nice to know when the funds(?) which is /are selling, have cleared though...

Yes agreed, I thought the article undersells Scancell's achievement so far, and real potential.

However the positive is that I've never seen IC write an article specifically about Scancell before!

So in taking a view that "any publicity is good publicity", it can only increase investor awareness.

Hopefully we will get some fresh investors who having done their own thorough research / due diligence, decide to buy a few.

"Scancell (SCLP) has stayed largely under the radar since in joined AIM in 2010. Founded in 1997, the company was launched based on research into immunotherapy by the University of Nottingham and came through the early 2000s biotech bust in the UK unscathed. Since then it has quietly developed several clinical candidates and has partnered with Danish biotech company Genmab to develop potential cancer antibodies. Genmab was the main source of newsflow during the half after it exercised an option for an anti-glycan antibody, SC2811, from Scancell's proprietary Glymab platform. The option meant a $6mn milestone payment to Scancell, which it will recognise in the year end accounts. If Genmab exercises all its options, Scancell could be in line for up to $630mn in total payments.

Higher R&D activity associated with clinical trials meant costs increased to £8mn (£5.7mn in 2023), but also led to higher R&D credits of £1.3mn. In terms of its overall debt position, total convertible notes were £19.2mn, which is shown on the balance sheet as the amortised cost of £14.8mn.

Scancell looks to be making steady, if unflashy progress with its development programmes. The company's early stage pipeline looks largely funded after a December capital fundraising of £11.3mn.

Whether the shares are good value will depend on how quickly it earns the milestones from its Genmab collaboration. A possible downside might be the dilution risk from the company's convertible loans, which are held by Scancell's largest shareholder Redmile Group. Redmile recently ammended the terms of the loans to allow it to convert them at any time."

IC provide a Hold recommendation

Okay growth slowed in H2, but 15% up on revenue in January compared to Jan 24, plus better margins.

Drop looks overdone to me.

Https://www.londonstockexchange.com/news-article/W7L/trading-update/16887210

FY revenue £102m, up 13.8% v last year

FY Profit £24m, up 32.6% v last year

January started well with revenue up 15% v last January

Solid results in tough trading environment.

Positive is growth in VLG own brand and recent H&H acquisition; which has real potential.

Share price looks really cheap if they can deliver forecast growth, EBITDA and profitability.

I'd like to see the debt reduced and no more acquisitions until they become profitable.

Buy and Hold.

Https://www.londonstockexchange.com/news-article/VLG/trading-statement/16882891

Exactly! When Goldman Sachs say Sell, they are actually Buying (and vice versa)!

Complete nonsense Broker rating, following on from strong results last week.

Https://www.londonstockexchange.com/news-article/VANL/interim-results-analyst-briefing-investor-pres/16873933

Decent performance in tough environment in H1

Order book up 24% v LY , ready for housing market to pickup.

Outlook for FY unchanged

The share price is being manipulated a bit as well - yesterday the U/T uncrossing trade was at 240p.

So today, when market makers opened up at the same prices it was trading yesterday i.e. 230p ask, 225 bid; the share price headline change shows RFX as being 5.21% down.

MMs trying to shake out a few cheap shares in my view.

Hold for excellent dividend and growth prospects - target 300p

+£80k worth of Director buys so far, since "profit warning"

+4% share price increase yesterday, expect more today in rising market.

+ Not every profit warning is text book; and I reckon RNWH with its strategic moats is stronger than most companies.

+ Largest order book on record

+ 10% drop in adj. op profit hardly warrants a 40% fall in last 3 months.

Wait on sidelines if you want whilst deliberating (hoping for cheaper in price), but I'm expecting to see £8/share soon

Its a delay on the railworks, not a contract loss.

Https://www.lse.co.uk/rns/VLX/trading-update-b2zo61i3xff65rx.html

Its the AGM on Monday, so its an opportunity for the Directors to reassure investors and funds that the rail work and delayed contracts are just a short term issue.

Renew (AIM: RNWH), the leading Engineering Services Group supporting the maintenance and renewal of critical infrastructure, announces that Mrs Dina Dasani, wife of Shatish Dasani, a Non-Executive Director and Chairman of the Audit and Risk Committee of the Group, has notified the Company that she purchased 3,000 ordinary shares of 10p each in the Company at a price of 712.1p per share.

As a result, Shatish Dasani, and connected parties, have a resultant holding in the Company of 24,000 shares representing 0.03% of the issued share capital.

Hi Accountant, today's drop is a great opportunity to buy into a really solid business, with clear visibility of revenue and "moats"; by which I mean knowledge, skills, licenses to work on railways, roads, nuclear installations etc. Its pretty much work that has to be done i.e. essential maintenance and repairs. Check out Renew's track record of delivering consistent growth, solid profits, and dividends (albeit small)

If you are not sure, best thing to do is take a small position and add to it or sell if the situation changes.

By buying a few, I find you then "follow the share", rather than forgetting about it when something else catches your eye!

I'm hoping we will get some Director buys over the next few trading days to push the share price up slightly!

Good luck, whatever decision you make.

Agree Guitarsolo, I see this as a temp blip. Order levels at record £905m and Adj Op profit above last years (£70.9m) but missing expected £79.1m... looks a massive over reaction to me and I've added more this morning.

Good update, particularly like the outlook "stronger H2 weighting" and special dividend.

Last year paid out 8.3p/share in dividends.

Assuming this year it will be around 8.7p plus 3.0p special dividend declared today - gives about 5.5% dividend at share price 215p.

Https://www.londonstockexchange.com/news-article/FNX/trading-update-and-special-dividend-declaration/16865476

Https://www.londonstockexchange.com/news-article/VANL/eight-year-electricity-transmission-agreement/16859306

It would be good if we got 1 or2 holding RNS's out over the next couple of days to confirm who is in and out.

- However suspect they may already be under the 3% declarable threshold or not reached that level on purchase..

Regardless, big volume of trades is normally a precursor for share price to re-rate.